

## Remidio invests in UK's Occuity to enhance eye healthcare

25 March 2025 | News

### Strategic partnership to advance early disease detection with cutting-edge optical technology



In a move set to redefine non-invasive disease detection, Bengaluru-based Remidio, a global leader in artificial intelligence (AI)-powered ophthalmic solutions, has made a strategic investment in Occuity, a pioneering UK-based developer of handheld, optical screening and monitoring devices that are non-contact and require no consumables.

Remidio and Occuity's partnership will begin with the integration of technologies to co-develop a comprehensive myopia screening solution, addressing India's growing myopia epidemic.

By 2050, nearly 48% of urban children are expected to be affected, with 20% experiencing rapid progression and around 4% facing complications that could lead to permanent vision loss.

A key part of this solution is the introduction of India's first-of-its-kind handheld, non-invasive, and highly accurate axial length measurement device for myopia detection and monitoring. This innovation eliminates the need for complex and expensive eye exams, making early diagnosis more accessible—particularly for children.

This collaboration will also introduce a novel non-contact, handheld device for accurately assessing corneal thickness—critical for managing glaucoma patients and evaluating suitability for interventions such as LASIK. This innovation will enhance Remidio's widely used Comprehensive Eye Clinic in a Bag, further extending access to comprehensive eye disease screening.

Leveraging Remidio's expertise in AI-powered diagnostics and scalable manufacturing, this collaboration will accelerate the development and deployment of Occuity's non-contact, handheld screening solutions globally.

This includes the Occuity Indigo, an optical glucose meter designed to measure glucose levels through a simple eye scan, eliminating the need for painful finger-prick tests currently endured by over 100 million diabetes patients in India. This will further strengthen Remidio's leadership in AI-driven detection of chronic eye diseases like Diabetic Retinopathy, Glaucoma and Macular Degeneration.